Ginkgo Bioworks (DNA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.27, -12.67% vs the prior close of $11.76.
- Volume 3.55M shares, 1.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DNA slides 12.7% to $10.27. Closed at $10.27, -12.67% vs the prior close of $11.76. Day range $10.12–$11.80, opened at $11.62.
DNA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DNA slides 12.7% to $10.27
- Closed at $10.27, -12.67% vs the prior close of $11.76. Day range $10.12–$11.80, opened at $11.62.
- Volume was 3.55M shares, 1.6x its 50-day average of 2.24M.
- Price is +16.3% vs its 50-day average ($8.83) and +20.8% vs its 200-day average ($8.50).
- 52-week range $5.37–$18.22; today's close sits at 38% of that range, 43.6% below the 52-week high.
Oct 15, 2026 — DNA rises 2.0% to $11.76
- Closed at $11.76, +1.99% vs the prior close of $11.53. Day range $10.40–$11.80, opened at $11.07.
- Volume was 2.33M shares, 1.1x its 50-day average of 2.21M.
- Price is +33.7% vs its 50-day average ($8.80) and +38.5% vs its 200-day average ($8.49).
- 52-week range $5.37–$18.22; today's close sits at 50% of that range, 35.5% below the 52-week high.
Oct 14, 2026 — DNA dips 2.0% to $11.53, 3 down days in a row
- Closed at $11.53, -1.96% vs the prior close of $11.76. Day range $11.24–$12.07, opened at $11.42.
- Volume was 1.76M shares, 0.8x its 50-day average of 2.20M.
- Price is +31.8% vs its 50-day average ($8.75) and +36.0% vs its 200-day average ($8.48).
- 52-week range $5.37–$18.22; today's close sits at 48% of that range, 36.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — DNA ends flat (-0.3%) to $11.76
- Closed at $11.76, -0.25% vs the prior close of $11.79. Day range $11.51–$12.45, opened at $11.79.
- Volume was 1.86M shares, 0.8x its 50-day average of 2.19M.
- Price is +35.1% vs its 50-day average ($8.71) and +39.0% vs its 200-day average ($8.46).
- 52-week range $5.37–$18.22; today's close sits at 50% of that range, 35.5% below the 52-week high.
Oct 12, 2026 — DNA slides 9.3% to $11.79
- Closed at $11.79, -9.31% vs the prior close of $13.00. Day range $11.26–$12.82, opened at $12.69.
- Volume was 2.60M shares, 1.2x its 50-day average of 2.15M.
- Price is +36.3% vs its 50-day average ($8.65) and +39.6% vs its 200-day average ($8.45).
- 52-week range $5.37–$18.22; today's close sits at 50% of that range, 35.3% below the 52-week high.
Oct 9, 2026 — DNA jumps 14.6% to $13.00 on 2.2x normal volume
- Closed at $13.00, +14.64% vs the prior close of $11.34. Day range $11.48–$13.56, opened at $11.76.
- Volume was 4.51M shares, 2.2x its 50-day average of 2.07M — unusually heavy trading.
- Price is +51.6% vs its 50-day average ($8.58) and +54.2% vs its 200-day average ($8.43).
- 52-week range $5.37–$18.22; today's close sits at 59% of that range, 28.6% below the 52-week high.
Oct 8, 2026 — DNA dips 1.1% to $11.34, 3 down days in a row
- Closed at $11.34, -1.13% vs the prior close of $11.47. Day range $10.61–$11.41, opened at $10.92.
- Volume was 3.21M shares, 1.6x its 50-day average of 2.02M.
- Price is +33.8% vs its 50-day average ($8.48) and +34.8% vs its 200-day average ($8.41).
- 52-week range $5.37–$18.22; today's close sits at 46% of that range, 37.8% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — DNA slides 7.6% to $11.47 on 3.4x normal volume
- Closed at $11.47, -7.57% vs the prior close of $12.41. Day range $10.81–$11.95, opened at $11.81.
- Volume was 6.45M shares, 3.4x its 50-day average of 1.91M — unusually heavy trading.
- Price is +36.5% vs its 50-day average ($8.40) and +36.7% vs its 200-day average ($8.39).
- 52-week range $5.37–$18.22; today's close sits at 47% of that range, 37.0% below the 52-week high.
Oct 6, 2026 — DNA slides 17.2% to $12.41 on 7.9x normal volume
- Closed at $12.41, -17.16% vs the prior close of $14.98. Day range $12.11–$18.22, opened at $15.08.
- Volume was 13.14M shares, 7.9x its 50-day average of 1.66M — unusually heavy trading.
- Price is +49.0% vs its 50-day average ($8.33) and +48.1% vs its 200-day average ($8.38).
- 52-week range $5.37–$18.22; today's close sits at 55% of that range, 31.9% below the 52-week high.
Oct 5, 2026 — DNA jumps 21.3% to $14.98, a 6-month high on 5.1x normal volume
- Closed at $14.98, +21.30% vs the prior close of $12.35. Day range $12.48–$15.48, opened at $12.50.
- Volume was 7.69M shares, 5.1x its 50-day average of 1.52M — unusually heavy trading.
- Price is +82.1% vs its 50-day average ($8.23) and +79.3% vs its 200-day average ($8.36).
- 52-week range $5.37–$17.58; today's close sits at 79% of that range, 14.8% below the 52-week high.
Oct 2, 2026 — DNA dips 1.2% to $12.35
- Closed at $12.35, -1.20% vs the prior close of $12.50. Day range $11.94–$13.40, opened at $13.00.
- Volume was 2.04M shares, 1.4x its 50-day average of 1.50M.
- Price is +52.9% vs its 50-day average ($8.08) and +48.4% vs its 200-day average ($8.32).
- 52-week range $5.37–$17.58; today's close sits at 57% of that range, 29.7% below the 52-week high.
DNA latest news & SEC filings
Every SEC filing by or about DNA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Coen Steven P. sold 2,403 shares at $15.00 (≈$36.05K) on Oct 5, 2026; now holds 49,448
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Henry Christian O sold 5,000 shares at $7.08 (≈$35.41K) on Sep 15, 2026; now holds 19,310
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Coen Steven P. sold 330 shares at $6.98 (≈$2.30K) on Aug 24, 2026
- Coen Steven P. sold 330 shares at $6.98 (≈$2.30K) on Aug 24, 2026
- Coen Steven P. sold 330 shares at $6.98 (≈$2.30K) on Aug 24, 2026
- Coen Steven P. sold 330 shares at $6.98 (≈$2.30K) on Aug 24, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $20.16M (prior year $39.13M) (-48.5% vs Jun 30, 2025)
- Net income: -$46.71M (prior year -$60.30M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.75 (prior year -$1.10) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 30, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade DNA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 8.29% (largest 21.3%). That is a volatile stock.
- Liquidity: about 3.84M shares (≈$39.40M) trade per day on average.
- 52-week position: $10.27 vs a range of $5.37–$18.22 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Christian O Henry sold 5,000 shares on Sep 15, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 5, 2026; 8-K Jul 30, 2026.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
DNA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.62 | 11.80 | 10.12 | 10.27 | 3.55M |
| Oct 15, 2026 | 11.07 | 11.80 | 10.40 | 11.76 | 2.33M |
| Oct 14, 2026 | 11.42 | 12.07 | 11.24 | 11.53 | 1.76M |
| Oct 13, 2026 | 11.79 | 12.45 | 11.51 | 11.76 | 1.86M |
| Oct 12, 2026 | 12.69 | 12.82 | 11.26 | 11.79 | 2.60M |
| Oct 9, 2026 | 11.76 | 13.56 | 11.48 | 13.00 | 4.51M |
| Oct 8, 2026 | 10.92 | 11.41 | 10.61 | 11.34 | 3.21M |
| Oct 7, 2026 | 11.81 | 11.95 | 10.81 | 11.47 | 6.45M |
| Oct 6, 2026 | 15.08 | 18.22 | 12.11 | 12.41 | 13.14M |
| Oct 5, 2026 | 12.50 | 15.48 | 12.48 | 14.98 | 7.69M |
| Oct 2, 2026 | 13.00 | 13.40 | 11.94 | 12.35 | 2.04M |
| Oct 1, 2026 | 12.60 | 13.16 | 12.11 | 12.50 | 2.92M |
| Sep 30, 2026 | 11.90 | 13.41 | 11.86 | 12.83 | 4.65M |
| Sep 29, 2026 | 10.54 | 12.27 | 10.53 | 11.96 | 4.75M |
| Sep 28, 2026 | 10.38 | 10.79 | 10.10 | 10.46 | 2.12M |
| Sep 25, 2026 | 10.20 | 10.67 | 9.54 | 10.66 | 2.31M |
| Sep 24, 2026 | 8.50 | 10.44 | 8.44 | 10.25 | 4.02M |
| Sep 23, 2026 | 9.13 | 9.28 | 8.54 | 8.58 | 1.84M |
| Sep 22, 2026 | 7.87 | 9.80 | 7.80 | 9.37 | 3.33M |
| Sep 21, 2026 | 8.05 | 8.13 | 7.67 | 7.98 | 1.65M |
About Ginkgo Bioworks
Ginkgo Bioworks (DNA) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1830214.
DNA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ross Fubini | Director | Jun 15, 2026 |
| Christian O Henry | Director | Sep 16, 2026 |
| Jason R Kelly | See remarks | Jul 30, 2026 |
| Sri Kosuri | Director | Jun 15, 2026 |
| Harry Sloan | Director | Jun 15, 2026 |
| Reshma P. Shetty | See remarks | Jul 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steven P. Coen | See remarks | Aug 25, 2026 |
| Jason R Kelly | See remarks | Jul 30, 2026 |
| Reshma P. Shetty | See remarks | Jul 30, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Christian O Henry | Sale | 5,000 | $7.08 |
| Sep 15, 2026 | Christian O Henry | Sale | 5,000 | $7.08 |
| Sep 15, 2026 | Christian O Henry | Sale | 5,000 | $7.08 |
| Sep 15, 2026 | Christian O Henry | Sale | 5,000 | $7.08 |
| Aug 24, 2026 | Steven P. Coen | Sale | 330 | $6.98 |
| Aug 24, 2026 | Steven P. Coen | Sale | 330 | $6.98 |
| Aug 24, 2026 | Steven P. Coen | Sale | 330 | $6.98 |
| Aug 24, 2026 | Steven P. Coen | Sale | 330 | $6.98 |
| Jul 17, 2026 | Steven P. Coen | Sale | 752 | $7.90 |
| Jul 17, 2026 | Steven P. Coen | Sale | 752 | $7.90 |
| Jul 17, 2026 | Steven P. Coen | Sale | 752 | $7.90 |
| Jul 17, 2026 | Steven P. Coen | Sale | 752 | $7.90 |
| May 22, 2026 | Steven P. Coen | Sale | 307 | $8.33 |
| May 22, 2026 | Steven P. Coen | Sale | 307 | $8.33 |
| May 22, 2026 | Steven P. Coen | Sale | 307 | $8.33 |
DNA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $170.16M | $-312.76M | -5.64 | $-171.06M |
| Dec 31, 2024 | $227.04M | $-547.03M | -10.54 | $-319.58M |
| Dec 31, 2023 | $251.46M | $-892.87M | -18.37 | $-295.50M |
| Dec 31, 2022 | $477.71M | $-2.10B | -50.20 | $-252.20M |
| Dec 31, 2021 | $313.84M | $-1.83B | -1.39 | $-253.82M |
Latest balance sheet: total assets $990.05M, total liabilities $569.76M, cash $84.53M (as of Jun 30, 2026).
DNA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $9.37 |
| May 7, 2026 | 8-K Item 2.02 (results) | $10.32 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $9.71 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $11.30 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $13.46 |
| May 6, 2025 | 8-K Item 2.02 (results) | $6.45 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $10.29 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $8.39 |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Jan 10, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DNA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.